Length of hospital stay · children hospitalised with an acute asthma exacerbation
1 finding from 1 review
Time to regular dose of short‐acting beta2‐agonists (hours) · children hospitalised with an acute asthma exacerbation
1 finding from 1 review
Asthma clinical scores · children hospitalised with an acute asthma exacerbation
Combination of anticholinergics + beta2‐agonists showed no clear difference in asthma clinical scores compared with beta2‐agonists alone (moderate certainty).
1 finding from 1 review
Incidence of admissions to the ICU · children hospitalised with an acute asthma exacerbation
1 finding from 1 review
Overall withdrawals · children hospitalised with an acute asthma exacerbation
Combination of anticholinergics + beta2‐agonists showed no clear difference in overall withdrawals compared with beta2‐agonists alone (moderate certainty).
1 finding from 1 review
Adverse health events · children hospitalised with an acute asthma exacerbation
1 finding from 1 review
Intervention not reported
SGRQ Scores range from 0 to 100, with higher scores indicating more limitations · 18 to 80 years of age with bronchiectasis
The intervention showed no clear difference in SGRQ Scores range from 0 to 100, with higher scores indicating more… (low certainty).
1 finding from 1 review
Intervention not reported
TDI Total scores range from ‐ 9 to +9. The lower the score, the greater the deterioration in severity of dyspnoea, MCID ≥ 1 · 18 to 80 years of age with bronchiectasis
The intervention may leads to higher TDI Total scores range from ‐ 9 to +9. The lower the score, the… (low certainty).
1 finding from 1 review
Intervention not reported
Cough‐free days Percentage of days free of cough · 18 to 80 years of age with bronchiectasis
The intervention may leads to higher cough‐free days Percentage of days free of cough (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations, number of participants with 1 or more exacerbations · 18 to 80 years of age with bronchiectasis
The intervention showed no clear difference in hospitalisations, number of participants with 1 or more exacerbations (low certainty).
1 finding from 1 review
Quality of life · adults with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations leading to health centre visits or exacerbations leading to hospitalisations Instrument: patient recorded · adults with asthma
1 finding from 1 review
FEV1 · adults with asthma
1 finding from 1 review
Medication usage Instrument: questionnaire · adults with asthma
1 finding from 1 review
Adverse events (a count of reported harms or adverse events/experiences over life of study/ · adults with asthma
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in exacerbations requiring steroids, antibiotics or both compared with placebo (moderate certainty).
1 finding from 1 review